| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
122,563,000 |
| Market
Cap: |
7.26(B) |
| Last
Volume: |
8,264,325 |
Avg
Vol: |
8,241,579 |
| 52
Week Range: |
$26.88 - $108.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
91,318 |
237,059 |
410,079 |
888,401 |
| Total Sell Value |
$6,319,460 |
$16,812,843 |
$22,688,654 |
$44,103,545 |
| Total People Sold |
2 |
4 |
5 |
11 |
| Total Sell Transactions |
4 |
16 |
36 |
82 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Malik Fady Ibraham |
EVP Research & Development |
• – – |
2021-01-14 |
4 |
AS |
$19.25 |
$240,619 |
D/D |
(12,500) |
150,441 |
|
12% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2021-01-14 |
4 |
OE |
$9.42 |
$117,750 |
D/D |
12,500 |
162,324 |
|
- |
|
| Kaye Edward M. Md |
Director |
– • – |
2021-01-04 |
4 |
A |
$19.56 |
$9,995 |
D/D |
511 |
511 |
|
- |
|
| Gage L Patrick |
Director |
– • – |
2021-01-04 |
4 |
A |
$19.56 |
$18,738 |
D/D |
958 |
21,762 |
|
- |
|
| Wysenski Nancy |
Director |
– • – |
2021-01-04 |
4 |
A |
$19.56 |
$4,988 |
D/D |
255 |
255 |
|
- |
|
| Wierenga Wendall D |
Director |
– • – |
2021-01-04 |
4 |
A |
$19.56 |
$9,995 |
D/D |
511 |
511 |
|
- |
|
| Califf Robert |
Director |
– • – |
2021-01-04 |
4 |
A |
$19.56 |
$4,988 |
D/D |
255 |
255 |
|
- |
|
| Henderson John T |
Director |
– • – |
2021-01-04 |
4 |
A |
$19.56 |
$9,995 |
D/D |
511 |
1,410 |
|
- |
|
| Smith Sandford D |
Director |
– • – |
2021-01-04 |
4 |
A |
$19.56 |
$9,995 |
D/D |
511 |
511 |
|
- |
|
| Henderson John T |
Director |
– • – |
2020-12-31 |
4 |
AS |
$20.31 |
$17,426 |
D/D |
(858) |
899 |
|
17% |
|
| Henderson John T |
Director |
– • – |
2020-12-31 |
4 |
OE |
$12.96 |
$11,120 |
D/D |
858 |
1,757 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2020-12-16 |
4 |
AS |
$20.51 |
$102,551 |
D/D |
(5,000) |
305,589 |
|
28% |
|
| Blum Robert I |
President & CEO |
• • – |
2020-12-16 |
4 |
OE |
$6.00 |
$30,000 |
D/D |
5,000 |
310,589 |
|
- |
|
| Cragg David |
SVP Human Resources |
• – – |
2020-12-15 |
4 |
D |
$21.00 |
$223,713 |
D/D |
(10,653) |
146,229 |
|
- |
|
| Cragg David |
SVP Human Resources |
• – – |
2020-12-15 |
4 |
OE |
$9.42 |
$156,994 |
D/D |
16,666 |
152,137 |
|
- |
|
| Gage L Patrick |
Director |
– • – |
2020-12-15 |
4 |
S |
$21.00 |
$162,038 |
D/D |
(7,716) |
20,804 |
|
-27% |
|
| Gage L Patrick |
Director |
– • – |
2020-12-15 |
4 |
OE |
$12.96 |
$99,999 |
D/D |
7,716 |
28,520 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2020-12-10 |
4 |
AS |
$20.13 |
$21,177 |
D/D |
(1,052) |
150,441 |
|
31% |
|
| Lampert Mark N |
See Explanation of Responses |
– – – |
2020-12-09 |
4 |
S |
$18.00 |
$7,757,172 |
D/D |
(430,954) |
463,244 |
|
-24% |
|
| Blum Robert I |
President & CEO |
• • – |
2020-11-23 |
4 |
AS |
$15.73 |
$78,644 |
D/D |
(5,000) |
304,868 |
|
50% |
|
| Blum Robert I |
President & CEO |
• • – |
2020-11-23 |
4 |
OE |
$6.00 |
$30,000 |
D/D |
5,000 |
309,868 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2020-11-12 |
4 |
AS |
$17.15 |
$21,112 |
D/D |
(1,231) |
150,951 |
|
38% |
|
| Blum Robert I |
President & CEO |
• • – |
2020-11-10 |
4 |
AS |
$16.50 |
$82,488 |
D/D |
(5,000) |
304,868 |
|
40% |
|
| Blum Robert I |
President & CEO |
• • – |
2020-11-10 |
4 |
OE |
$6.00 |
$30,000 |
D/D |
5,000 |
309,868 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2020-10-29 |
4 |
AS |
$15.15 |
$75,773 |
D/D |
(5,000) |
304,868 |
|
31% |
|
1103 Records found
|
|
Page 20 of 45 |
|
|
0.91 (1.51%) 
